Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 23, 2026
TickeronGET DAILY SIGNALS
Why Is Sutro Biopharma (STRO) Stock Down -7.39% Today?

Why Is Sutro Biopharma (STRO) Stock Down -7.39% Today?

Key Takeaways

  • Sutro Biopharma (STRO) shares were down about 7.39% in intraday trading, trading near $9.53 versus a prior close of $10.29.
  • The decline reflects continued selling pressure in a stock that has already fallen sharply over the past month, with no single company-specific announcement driving today's move.
  • Lingering investor concerns over the progress of the lead STRO-004 Phase 1 program, following a mixed early data update, remain a key overhang.
  • The slide extends a broader downtrend for clinical-stage oncology names, with the stock trading well below its 50-day and 200-day moving averages.
  • Traders are watching whether shares can hold the $10 psychological level and for the next earnings report, expected in early November.
  • For additional details on Price Targets, Earnings, and Forecast data, explore the dedicated pages on Tickeron.
  • Discover how AI-driven strategies are trading this and other tickers by exploring Trending AI Robots.

Opening Summary

Sutro Biopharma, Inc. (STRO) is a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) for cancer, built around its proprietary cell-free protein synthesis platform. In today's session, the stock extended its recent decline, falling roughly 7.39% to trade near $9.53, compared with a prior close of $10.29. The move pushed shares below the closely watched $10 level and came without a fresh, single catalyst, suggesting the weakness reflects persistent negative sentiment and ongoing technical selling rather than a discrete new development.

Lingering Pressure on the STRO-004 Program

The most significant overhang on STRO traces back to the company's second-quarter update, when early Phase 1 data for its lead tissue factor-targeting ADC, STRO-004, revealed challenges that disappointed investors. Although the update pointed to some confirmed and unconfirmed partial responses, the market has remained skeptical about the pace and durability of the program's progress. That skepticism has kept a lid on the stock and contributed to repeated bouts of selling as traders reassess the risk profile of the lead asset.

Profit-Taking After Pipeline Announcements

Earlier this week, STRO announced it had dosed the first patient in a Phase 1 trial of STRO-006, its next-generation ITGB6-targeting ADC. While pipeline progress is generally viewed as a positive, the market has treated such updates with a "sell-the-news" mentality amid the stock's broader downtrend. With initial clinical data for STRO-006 not expected until the second half of 2027, near-term catalysts remain limited, leaving the shares vulnerable to profit-taking and momentum-driven selling.

Market Context and Trading Activity

The decline in STRO is part of a pronounced technical breakdown. The stock has lost roughly 36% over the past month and more than 55% over the past three months, and it now trades well below its 50-day and 200-day moving averages. Momentum indicators have signaled oversold conditions, yet buyers have failed to step in with conviction. The breach below the $10 round-number level today added to the bearish tone, and the move occurred against a backdrop of tepid risk appetite for small-cap and clinical-stage biotech names, which have underperformed broader market averages in recent weeks.

What Comes Next for STRO

Looking ahead, investors will focus on STRO's next quarterly earnings report, which is expected in early November, for updates on the STRO-004 program, cash runway, and any strategic adjustments. Key uncertainties include the durability of early responses in the lead program, the timeline for additional clinical data, and the company's funding position for advancing its broader pipeline. While analyst sentiment has remained broadly constructive relative to the current share price, the disconnect between high price targets and the stock's depressed level underscores the market's near-term caution. Risks include further clinical setbacks, dilution, and continued weakness across the biotech sector.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are currently among the strongest performers in live market conditions. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing strategies are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to observe how data-driven systems are navigating volatile names like STRO. Explore the page to see which AI strategies are gaining traction today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: STRO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


STRO in +15.33% Uptrend, advancing for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STRO advanced for three days, in 205 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STRO's RSI Indicator exited the oversold zone, 41 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for STRO just turned positive on November 02, 2026. Looking at past instances where STRO's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRO as a result. In 69 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for STRO entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.544) is normal, around the industry mean (3.596). P/E Ratio (-0.554) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. STRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of new products in protein vaccines and therapeutics

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
111 Oyster Point Boulevard
Phone
+1 650 881-6500
Employees
137
Web
https://www.sutrobio.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.